5th Circuit Affirms That Abilify Tardive Dyskinesia Claim Is Prescribed By State Law

(May 18, 2017, 1:18 PM EDT) -- NEW ORLEANS — The Fifth Circuit U.S. Court of Appeals on May 17 affirmed a district court’s finding that a plaintiff's neurological injury claim involving the atypical antipsychotic drug Abilify was filed too late (Cory Jenkins v. Bristol-Myers Squibb Company, et al., No. 16-31133, 5th Cir., 2017 U.S. App. LEXIS 8673)....

Attached Documents

Related Sections